Digest Network Come funziona
Network
/
Società
Va
Non verificato

Vasomune Therapeutics, Inc.

Di cosa scriviamo

BiotecnologiaFarmaceuticaIndustriaSaluteScienza

6 comunicati stampa

Guarda tutti i comunicati
27/07/2026
Eventi
Industria
Scienza
Medicina - Varie
Cardiologia
Biotecnologia
Farmaceutica
Salute
Difesa / Forze Armate
Vasomune Therapeutics to Present on Pegevongitide Therapeutic Capability at the 2026 NATO NSPA CBRN
Fonte
Vasomune Therapeutics, Inc.
Emittente
Business Wire
1.00
0
21/07/2026
Scienza
Cardiologia
Biotecnologia
Difesa / Forze Armate
Farmaceutica
Salute
Eventi
Industria
Vasomune Therapeutics to Present on Vascular Leak in Combat-Relevant Injury at the 2026 Military Health System Research Symposium
Fonte
Vasomune Therapeutics, Inc.
Emittente
Business Wire
1.00
0
24/03/2026
Industria
Scienza
Biotecnologia
Farmaceutica
Salute
Medicina - Varie
First Patient Dosed in New Study Investigating Novel Made-In-Canada Drug Candidate to Prevent Brain Injury in Hemodialysis Patients
Fonte
Vasomune Therapeutics, Inc.
Emittente
Business Wire
1.00
0
04/03/2026
Mercato del lavoro
Industria
Scienza
Biotecnologia
Farmaceutica
Sanità
Salute
Igiene alimentare
Medicina - Varie
Vasomune Therapeutics, Inc., and AnGes, Inc., Announce US FDA Clearance of Investigational New Drug (IND) Application For Pegevongitide (AV-001) Treatment in Resuscitation of Severely Burned Patients
Fonte
Vasomune Therapeutics, Inc.
Emittente
Business Wire
1.00
0
03/09/2025
Scienza
Cardiologia
Biotecnologia
Farmaceutica
Salute
Medicina - Varie
Mercato del lavoro
Industria
Health Canada Gives Green Light to New Study Investigating Novel Made-In-Canada Drug Candidate to Prevent Brain Injury in Hemodialysis Patients
Fonte
Vasomune Therapeutics, Inc.
Emittente
Business Wire
1.00
0
03/12/2024
Industria
Scienza
HIV, AIDS e malattie autoimmuni
Medicina - Varie
Cardiologia
Biotecnologia
Sanità
Salute
Farmaceutica
Vasomune and AnGes Announce Drug Candidate AV-001 Receives Positive IDSMB Recommendation to move to the High-Dose Cohort for AV001-004 Phase 2a Study
Fonte
Vasomune Therapeutics, Inc.
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0